Karen Flynn, President Biologics & CCO at Catalent, Inc. (CTLT), sold 99 shares at $104.42 ($10K) on 2021-01-04, disclosed to the SEC on 2021-01-05.
Scheduled sale ($10k) by President Biologics & CCO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CTLT | SELL | 2021-01-11 | $433K | — | Filing → |
| WST | SELL | 2018-08-09 | $4.8M | — | Filing → |
| REPH | BUY | 2016-12-19 | $5K | — | Filing → |